Skip to main content

Table 1 Patient characteristics

From: Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study

 

N = 18

Age (years)

80.5 (75–89)a

Sex

 Male/female

6/12

Performance status

 0/1/2/3

1/9/5/3

Body weight (kg)

47.7 (38.3–65.7)a

Serum albumin level (g/dL)

3.6 (1.6–4.5)a

Total bilirubin level (mg/dL)

0.6 (0.4–1.0)a

Serum creatinine level (mg/dL)

0.73 (0.38–1.14)a

eGFR (mL/min)

60.2 (48.5–115)a

EGFR mutation

 Exon 19/exon 21

8/10

  1. eGFR estimated glomerular filtration rate, EGFR epidermal growth factor receptor
  2. aData represented the median (range)